Cathy Eng, MD, FACP, FASCO

home / authors / cathy-eng-md-facp-fasco

Articles

The Ideal Patient for Biomarker Testing in Anal Carcinoma

The Ideal Patient for Biomarker Testing in Anal Carcinoma

Cathy Eng, MD, FACP, FASCO
July 2nd 2022

Cathy Eng, MD, FACP, FASCO, discusses the types of patients who should be tested for biomarkers in the anal cancer space.

The Role of Biomarker Testing in Anal Cancer

The Role of Biomarker Testing in Anal Cancer

Cathy Eng, MD, FACP, FASCO
August 8th 2021

Cathy Eng, MD, FACO, FASCO, discusses how biomarkers are being explored to aid the treatment of anal cancers.

NTRK Fusion–Positive Colon Cancer: Final Thoughts

NTRK Fusion–Positive Colon Cancer: Final Thoughts

Cathy Eng, MD, FACP, FASCO
May 4th 2020
NTRK-Targeted Therapy in Colon Cancer: Dosing and Management

NTRK-Targeted Therapy in Colon Cancer: Dosing and Management

Cathy Eng, MD, FACP, FASCO
May 4th 2020
NTRK-Targeted Therapy for Patients With Colon Cancer

NTRK-Targeted Therapy for Patients With Colon Cancer

Cathy Eng, MD, FACP, FASCO
May 4th 2020
Treatment Options for NTRK Fusion–Positive mCRC

Treatment Options for NTRK Fusion–Positive mCRC

Cathy Eng, MD, FACP, FASCO
May 4th 2020
Testing for NTRK Fusion–Positive Metastatic Colon Cancer

Testing for NTRK Fusion–Positive Metastatic Colon Cancer

Cathy Eng, MD, FACP, FASCO
May 4th 2020
Case-Based Overview: NTRK Fusion–Positive mCRC

Case-Based Overview: NTRK Fusion–Positive mCRC

Cathy Eng, MD, FACP, FASCO
May 4th 2020
A 68-Year-Old Woman with Metastatic NTRK Fusion-Positive Colon Cancer

A 68-Year-Old Woman with Metastatic NTRK Fusion-Positive Colon Cancer

Cathy Eng, MD, FACP, FASCO
May 4th 2020

Cathy Eng, MD, FACP, FASCO, reviews the case of a 68-year-old diagnosed with metastatic NTRK fusion-positive colon cancer and shares treatments options.

Latest Updated Articles

FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Innovative ctDNA Testing Drives Progress in NSCLC Research
Published: November 20th 2024 | Updated: November 23rd 2024
Innovative ctDNA Testing Drives Progress in NSCLC Research
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
Published: November 13th 2024 | Updated: November 23rd 2024
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
Immunotherapy Options for an Older Patient With Metastatic Melanoma
Published: August 18th 2023 | Updated: November 23rd 2024
Immunotherapy Options for an Older Patient With Metastatic Melanoma
Expert Takeaway From WCLC Congress Highlights Innovative ADC Showing Promise in SCLC
Published: October 19th 2024 | Updated: November 23rd 2024
Expert Takeaway From WCLC Congress Highlights Innovative ADC Showing Promise in SCLC
Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer
Published: June 6th 2024 | Updated: November 23rd 2024
Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer